3 Australian Growth Stocks To Own In September 2026

Global energy prices are in focus again as Middle East risks keep inflation debates alive. For Australian investors this puts extra attention on companies that analysts expect to lift earnings even if borrowing costs stay sensitive to inflation news. That is where this selection of financially sound, higher growth potential Australian stocks comes in. This article highlights three standouts from that group and explains what makes each one worth a closer look.

The stocks in this article are just a small sample of the healthy high growth potential opportunities that meet these financial quality checks. The full screen surfaced 92 more companies with similarly compelling stories that are not covered here. If you want to quickly narrow that broader list to ideas that truly fit your own risk and return preferences, head straight to the Healthy high growth potential screener.

Elevra Lithium (ASX:ELV)

Elevra Lithium is a Brisbane based miner focused on lithium, graphite and gold, with its 100% owned North American Lithium project in Quebec as the main engine that links it to the Healthy high growth potential theme. The business currently generates about US$201.7 million from this project through production of lithium concentrate for electric vehicle and energy storage supply chains. Elevra Lithium has a market value of roughly A$1.52b, which puts it in the mid cap bracket on the ASX.

Investors looking at Elevra Lithium are really looking at the North American Lithium project and its staged expansion, which already supports more than US$200 million in annual sales and has fresh offtake deals with Mangrove Lithium that include price floors and long contract lives. The company has recently moved into profitability with positive underlying EBITDA. Analysts identify earnings growth potential from here, yet the growth plan still depends on successful brownfield expansion, new refining capacity and ongoing access to funding. That mix of real cash generating operations, large scale growth projects and execution risk means anyone interested in the lithium supply chain may want to take a closer look at how Elevra Lithium’s next few years could reshape its earnings profile.

Elevra Lithium already has real cash generation from North American Lithium, yet the bigger story is what that growth pipeline could mean for future earnings. Get the full context in the analyst forecasts for Elevra Lithium

4DMedical (ASX:4DX)

4DMedical is a medical technology company focused on non invasive, four dimensional lung imaging software and scanners that help clinicians track respiratory disease over time, which aligns closely with the Healthy high growth potential theme around advanced diagnostics and monitoring. The company currently generates about A$7.1 million in revenue from its lung function analysis activities, largely in the United States, and has a market value of roughly A$2.2b. That combination of highly specialised lung imaging tools and growing commercial exposure makes 4DMedical an example of how software driven healthcare can support both clinical decisions and earnings growth potential.

Investors watching 4DMedical are really weighing up whether its XV LVAS and CT:VQ platforms can move from early adoption in major U.S. academic medical centres to wider routine use. Forecasts point to very strong earnings and revenue growth over the next three years, backed by regulatory clearances, new partnerships with groups such as Azra AI and a reported pro forma cash balance above A$200 million that supports the current scale up phase. The company is still loss making, with a recent full year loss of A$204.44 million and reliance on external funding and equity raises, so execution risk and further dilution are real considerations. If the planned rollout across leading hospitals and health systems continues to build, the shift from high potential to a more mature commercial model could be significant for patient care and for the stock’s risk reward profile.

4DMedical’s growth story is accelerating, yet many investors may not be joining the dots between its revenue base, cash position and scale up plans. See how that picture fits together in the analyst forecasts for 4DMedical

Neuren Pharmaceuticals (ASX:NEU)

Neuren Pharmaceuticals is a Hawthorn East based biopharma company focused on treatments for rare neurological disorders, with its commercialized drug DAYBUE for Rett syndrome providing the clearest link to the Healthy high growth potential earnings theme. Almost all of its recent commercial revenue, about A$69.5 million from commercial products, is tied to this therapy, while earlier stage programs such as NNZ-2591 for Phelan-McDermid, Angelman and Pitt Hopkins remain longer term options. Neuren Pharmaceuticals has a market value of roughly A$2.58b.

For investors looking for earnings growth that is backed by a real product rather than just a pipeline, Neuren Pharmaceuticals offers DAYBUE royalties and milestones already flowing through the P&L, plus the possibility of broader Rett and Fragile X uptake and international launches. The company also has cash coming in from its Acadia partnership and has flagged a share buyback and dividends, which hints at balance sheet strength and shareholder friendly capital management. The trade off is heavy reliance on DAYBUE sales, regulatory decisions and U.S. payers such as Medicaid, so setbacks in approvals, pricing or coverage could quickly affect revenue and margins. Anyone weighing that mix of rare disease cash flows, expansion plans and concentration risk may want to look more closely at how the next few years of DAYBUE performance could reshape Neuren's earnings profile and valuation story.

Neuren Pharmaceuticals has cash flows from DAYBUE, a pipeline of rare disease options and hinted capital returns that many investors may not yet be fully weighing. See how the royalty stream, buyback plans and concentrated risks line up in the analysis report for Neuren Pharmaceuticals

Seeking Fresh Alternatives Before They Fly

Fresh ideas do not stay under the radar for long. Once momentum builds and prices start flying, the most attractive entry points can be harder to find. Consider researching potential opportunities early.

• Scan for cash rich companies quietly building momentum with the list of solid balance sheet and fundamentals (21 results) before the crowd starts pricing in their financial strength.
• Explore income opportunities that aim to keep paying investors while others focus on hype by reviewing the 8 dividend fortresses while yields still look appealing.
• Look for future-facing infrastructure exposure by checking the 55 AI infrastructure stocks while these enablers of AI demand may still be relatively less discussed.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com